Background: The lack of definitive scientific evidence sustains uncertainty about the efficacy of glucosamine and its combination therapies for knee osteoarthritis (KOA), contributing to an ongoing debate among clinical practice guidelines and healthcare practitioners. This systematic review and network meta-analysis (NMA) aimed to identify the most effective glucosamine combination therapy for KOA patients. Methods: Frequentist random-effects models were employed for this NMA, with standardized mean differences (SMDs) and 95% confidence intervals (CIs) calculated for primary outcomes. We incorporated an SMD value of 0.40 as a minimum clinically important difference (MCID) to interpret the pain outcome. Confidence in evidence was evaluated using CINeMA. Results: Thirty randomized controlled trials (RCTs) covering 5265 patients were included. Glucosamine with omega-3 (G + omega-3, SMD –2.59 [95% CI –4.42 to –0.75], moderate quality) and glucosamine with ibuprofen (G + ibuprofen, SMD –2.27 [95% CI –3.73 to –0.82], moderate quality) significantly reduced overall pain compared to placebo. Similarly, glucosamine + chondroitin sulfate + methylsulfonylmethane showed effectiveness in pain reduction (SMD –2.25 [95% CI –3.84 to –0.67], low-quality). None of the other interventions met the MCID threshold for overall pain reduction. Moreover, clustered ranking results showed that glucosamine with omega-3 interventions was more effective than others in reducing overall pain and adverse events. Conclusions: For KOA, combining glucosamine with omega-3 and ibuprofen effectively reduces pain and may lower NSAID side effects, improving treatment guidelines and decision-making for better patient care.
Background: The skin acts as a barrier against external threats, and moisture is crucial for effective wound healing, as it promotes epithelial cell migration. Thus, a high water content supports wound healing by maintaining moisture, absorbing exudate, and forming a protective barrier. Here, we created three different micro-patterned hydrogels and tested them on rat skin wounds. Materials and Methods: Three different micro-patterned (waves, lines, and checks) hydrogel patches were created using three-dimensional polymer networks. On SD rat skin, wounds were created by making incisions, and the hydrogel patches were applied. The rats were divided into three experimental groups based on the hydrogel micro-patterns. Rats without hydrogel (vehicle) and those with flat hydrogel (no shape) were considered as controls. The wound closure rate (WCR) was calculated, and the expression of Col1A protein was measured by western blot. Results: After 7 days, the WCR was significantly higher in the groups treated with micro-patterned hydrogel patches compared to the vehicle and no-shape groups. Specifically, the WCR was highest in the checks micro-patterned hydrogel group compared to the waves and lines micro-patterned hydrogel groups. Furthermore, Col1A protein expression was evaluated at days 7 and 14, revealing a significant increase in expression after 14 days in the checks micro-patterned hydrogel group compared to the waves and lines micro-patterned hydrogel groups. Conclusions: The checks micro-patterned hydrogel patches demonstrated superior wound healing efficacy, as indicated by a higher WCR and increased Col1A protein expression after 14 days. These findings highlight the importance of hydrogel pattern design in improving wound healing suggesting that optimized micro-patterns can enhance therapeutic outcomes in skin wound management.
In this study, we developed a pneumatically driven microfluidic platform (PDMFP) operated by a fully automated particle concentration system (FAPCS) for the pretreatment of micro- and nano-sized materials. The proposed PDMFP comprises a 3D network with a curved fluidic chamber and channel, five on/off pneumatic valves for blocking fluid flow, and a sieve valve for sequential trapping of microbeads and target particles. Using this setup, concentrated targets are automatically released into an outlet port. The FAPCS mainly comprises solenoid valves, glass reservoirs, a regulator, pressure sensor, main printed circuit board, and liquid crystal display touch panel. All pneumatic valves in the microfluidic platform as well as the working fluids in the glass reservoirs are controlled using FAPCS. The flow rate of the working fluids is measured to demonstrate the sequential programed operation of the proposed pretreatment process using FAPCS. In our study, we successfully achieved rapid and efficient enrichment using PDMFP-FAPCS with fluorescence-labeled Escherichia coli. With pretreatment-10 min for the microbead concentration and 25 min for target binding-almost all the target bacteria could be captured. A total of 526 Gram-negative bacteria were attached to 82 beads, whereas Gram-positive bacteria were attached to only 2 of the 100 beads. Finally, we evaluated the PDMFP-FAPCS for SARS-CoV-2 receptor-binding domain (RBD)-based outer membrane vesicles (OMVs) (RBD-OMVs). Specific probes involved in PDMFP-FAPCS successfully isolated RBD-OMVs. Thus, PDMFP-FAPCS exhibits excellent enrichment of particles, including microbes and nanovesicles, and is an effective pretreatment platform for disease diagnosis and investigation.
9 July 2020 in Journal of Bioactive and Compatible Polymers
Poly lactic-co-glycolic acid particles are biodegradable and biocompatible drug delivery systems that provide a controlled release of drugs in specific sites. These characteristics minimize the occurrence of side effects related to overdosing. To overcome the issues associated with the conservative treatment for wound healing, the objective of this work was to develop a poly lactic-co-glycolic acid particles system to deliver anti-inflammatory compounds (epigallocatechin gallate and asiaticoside) to fibroblasts. Nanoscale (~200 nm) and microscale (~10 µm) poly lactic-co-glycolic acid particles were produced using two different protocols. Nanoscale particles reduced cell proliferation by 46% compared with untreated human skin fibroblasts, whereas microscale particles did not affect fibroblast viability significantly. The toxicity of nanoparticles and the nontoxic nature of microparticles were confirmed in live and dead cell staining experiments. In vitro drug release assays showed that particles containing epigallocatechin gallate and asiaticoside were able to release most of their payload during the first 8 h of incubation. The treatment of lipopolysaccharide-stimulated fibroblasts with epigallocatechin gallate- and asiaticoside-loaded microparticles effectively suppressed the expression of inflammatory factors: tumor necrosis factor-α, interleukin-1β, and interleukin-6. In this study, we found that the optimal size of biodegradable poly lactic-co-glycolic acid particles for the delivery of physiologically active substances to fibroblasts is about 10 μm. Moreover, our findings indicate that poly lactic-co-glycolic acid particles of this size can be effectively applied to ameliorate tissue regeneration by delivering physiologically active substances to improve skin lesion recovery.
Alginate hydrogels offer mild ionic gelation and tunable porosity for drug delivery, yet their hydrophilic, macroporous networks suffer from rapid initial burst release of water-soluble payloads. Here we introduce a hierarchical barrier-engineering strategy in which poly(D,L-lactide-co-glycolide)/poly(ethylene glycol) (PLGA/PEG) blend coatings are applied via dip-coating to Ca2+-cross-linked alginate beads (~1 mm) and microgels (~100 µm). For beads, three-cycle PLGA/PEG multilayer coating suppressed the initial swelling rate (dQ/dt) by ~50% and reduced 1 h burst release from >85% to ~60%, functioning as an “early-burst buffer” rather than a long-term depot. For microgels, a single PLGA/PEG layer partially attenuated burst release; however, an additional PLGA outer shell (double-barrier architecture) shifted the release-governing mechanism from swelling-dominated to diffusion-barrier-dominated control, limiting 10 min release to 50% for beads, >20% for microgels) without compromising gel integrity. In beads, burst control was governed by swelling suppression; in microgels, the additional PLGA shell shifted control to diffusion-barrier-dominated release, demonstrating that barrier architecture must be adapted to particle scale.